Moxonidin Actavis (Moxonidine)

Moxonidine, the active ingredient in Moxonidin Actavis, is a imidazoline receptor agonist presented as an oral tablet for oral use. It treats essential hypertension in adult patients. GNH USA supplies Moxonidin Actavis as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Moxonidine acts on central imidazoline I1 receptors to lower blood pressure in hypertensive disorders. Essential hypertension: reduces systolic and diastolic pressure in patients with primary hypertension. Resistant hypertension: may be added when blood pressure remains uncontrolled despite other antihypertensive agents.

Moxonidine is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Dry mouth: sensation of oral dryness. - Fatigue: feeling of tiredness or lack of energy. - Dizziness: light‑headedness, especially on standing. - Nausea: mild stomach upset.

Serious or Rare Side Effects: - Severe hypotension: marked drop in blood pressure requiring medical attention. - Bradycardia: unusually slow heart rate. - Allergic reaction: rash, itching, swelling, or difficulty breathing. - Hepatic dysfunction: abnormal liver enzyme elevations. - Cardiac arrhythmia: irregular heart rhythm.

Before initiating therapy, consider the following safety measures. - Renal impairment: monitor renal function and adjust therapy as needed. - Hepatic impairment: use with caution; observe liver function tests. - Concomitant antihypertensives: risk of additive blood‑pressure lowering effects. - Pregnancy: safety not established; avoid unless clearly indicated. - Elderly patients: increased risk of dizziness and falls; monitor closely. - Store at room temperature: keep in the original container, protect from moisture and light.

Moxonidine may interact with several drug classes; review patient medication lists.

Major Interactions (Avoid): - Other central antihypertensives (e.g., clonidine): may cause severe hypotension. - Potent CYP2D6 inhibitors: can increase moxonidine plasma concentrations. - Diuretics: may exacerbate electrolyte disturbances.

Moderate Interactions (Monitor Closely): - NSAIDs: may diminish antihypertensive effect. - Beta‑blockers: may mask tachycardia associated with hypotension.